Scienmag

JUNE 3, 2022

Researchers at Baylor College of Medicine and Texas Children’s Hospital have identified potent, highly specific compounds that interfere with bromodomain (BD)-containing proteins involved in cancer.

Containment 64

Containment Protein Medicine Development 64

Scienmag

JANUARY 20, 2022

Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor, which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators. The study results, published on Nov.

Packaging 58

Packaging Packaging Doctors Doctor 58

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Scienmag

MAY 18, 2021

(Boston)–Researchers from Boston University School of Medicine (BUSM) report the formation of human cells containing a green fluorescent protein or GFP (one of the most important proteins in biology and fluorescence imaging) genetically fused with two interferon stimulated genes (ISGs), namely Viperin and ISG15.

Immune Response 41

Immune Response Reagent Research Protein 41

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Essentially, a biologic is a product that is produced from living organisms or that contains components of living organisms.

Development 180

Development Protein Production Hormones 180

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

pharmaphorum

MAY 11, 2021

Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body. This makes the body into a “drug factory”, allowing for long-lasting medicines that allow for repeat redosing and can be administered easily by several routes.

RNA 98

RNA Drugs Protein Immune Response 98

XTalks

DECEMBER 5, 2023

Augtyro, a tyrosine kinase inhibitor (TKI), is available as oral capsules, each containing 40 mg of repotrectinib. As its active ingredient, repotrectinib inhibits the proto-oncogene tyrosine-protein kinase ROS1 and the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB and TRKC.

Protein 115

Protein FDA Approval Medicine Trials 115

Pharmaceutical Technology

FEBRUARY 15, 2023

Cas, also called CRISPR associated proteins, are a family of nucleases such as Cas9, Cas12a, Cas12b, and CasX that process these sequences. The eukaryotic genome can be cut at any desired position by introducing plasmids containing Cas genes and specifically constructed CRISPRs into eukaryotic cells.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Scienmag

NOVEMBER 20, 2020

It contains the information for the production of 27 proteins. This is not much compared to the possible 40,000 kinds of protein that a […].

Genome 70

Genome Genomics RNA Protein 70

Pfizer

SEPTEMBER 28, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted The information contained in this release is as of September 28, 2022. Tue, 09/27/2022 - 16:15. Pfizer Disclosure Notice.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Drug Discovery World

APRIL 11, 2023

Key features of the Spring issue include a market report on the US drug discovery sector, whether AI can discover new medicines, and why post-Covid-19 cognitive impairment is a new target for drug development. To download the DDW app for Apple devices click  here.

Containment 52

Containment Protein Drugs Medicine 52

XTalks

JANUARY 3, 2024

Polydefkis, professor of Neurology at Johns Hopkins University School of Medicine and an investigator in the Phase III NEURO-TTRansform study on which Wainua’s FDA approval was grounded on, in the news release. The accumulation of TTR fibrils disrupts the usual functions of these tissues.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

Pharmaceutical Technology

MAY 24, 2023

Innovation S-curve for the pharmaceutical industry Tetrapeptide derivatives are a key innovation area in the pharmaceutical industry Tetrapeptides are classified as oligopeptides as they contain only four amino acids linked by peptide bonds.

Protein 130

Protein Antibody Medicine Development 130

Pharmaceutical Technology

JUNE 24, 2022

The mRNA-1273.214 booster contains the original Spikevax vaccine and a candidate targeting Omicron BA.1 5, there may be enough overlap for the bivalent vaccine to offer protection against all the subvariants, says Dr Prathit Kulkarni, assistant professor of medicine in infectious diseases at Baylor College of Medicine.

Vaccination 264

Vaccination Vaccine Antibody Medicine 264

Pharmaceutical Technology

JULY 29, 2022

Pfizer completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent Covid-19 vaccine candidate, based on the BA.1 And we are very prepared and have data that will answer those questions, what would be the advantage of shifting to an Omicron-containing vaccine, whether it's monovalent or bivalent.”

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

Drug Discovery World

JANUARY 31, 2024

It is also exciting that the data from the OLE show that switching to atacicept halted the eGFR decline seen in participants initially treated with placebo,” stated Richard Lafayette, Professor of Medicine, Nephrology and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center.

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

XTalks

AUGUST 26, 2020

. “We found that macrophage programming is driven by more than the immune system — it is also driven by the environment in which the macrophages reside,” said lead study author Asrar Malik, the UIC Schweppe Family Distinguished Professor and head of pharmacology and regenerative medicine at the College of Medicine.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

Pfizer

AUGUST 3, 2022

mitogen activated protein kinase pathway, which demonstrated improvement in functional capacity (6-minute walk test; 6MWT) in a 48-week, open-label, Phase 2 study among patients with symptomatic LMNA-related DCM. The information contained in this release is as of August 3, 2022. Disclosure Notice.

Development 101

Development Vaccination Vaccine Production 101

XTalks

DECEMBER 20, 2021

Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Covovax is a protein subunit vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine demonstrated an overall efficacy of 90.4

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

pharmaphorum

OCTOBER 2, 2020

It’s an historic announcement, bringing hope that the vaccine could be approved in the near future, although the European Medicines Agency did not say how long the process will take. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Regulation 100

Regulation Vaccination Vaccine Protein 100

Pharmaceutical Technology

OCTOBER 28, 2022

It aims to ensure the quality of medicines by employing statistical, analytical, and risk-management methodology in the design, development, and manufacturing processes of medicines. There are many variabilities with biosimilars and the brand name protein drug.” For biosimilars, however, this process is slightly more complex.

Bioequivalency 130

Bioequivalency Production Branding Contamination 130

Drug Discovery World

AUGUST 9, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T cell therapy.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Licensing 52

Pfizer

AUGUST 11, 2022

The information contained in this statement is as of August 11, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. . Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 07.19.2022.

Containment 49

Containment Vaccination Vaccine Development 49

The Pharma Data

SEPTEMBER 14, 2020

. AstraZeneca has confirmed that clinical trials assessing its Oxford University partnered coronavirus vaccine AZD1222 have resumed in the UK, following a green light by the Medicines Health Regulatory Authority (MHRA). Source link.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. A UK safety committee has concluded its investigations and recommended to the country’s Medicines and Healthcare products Regulatory Agency (MHRA) that trials are safe to resume.

Vaccination 77

Vaccination Vaccine Trials Protein 77

The Pharma Data

JULY 28, 2021

The analysis was conducted using AstraZeneca’s global safety database, which captures all spontaneously reported adverse events from real-world use of its medicines and vaccines worldwide. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccination 52

Vaccination Vaccine Medicine Protein 52

The Pharma Data

DECEMBER 10, 2020

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000 program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases.

Containment 52

Containment Clinical Development Development Protein 52

XTalks

AUGUST 6, 2020

Epidiolex is the only FDA-approved formulation that contains CBD derived from the cannabis plant. CBD is the most abundant non-psychoactive cannabinoid compound found in the cannabis plant, making up about 40 percent of the plant’s extract, which contains over 100 different cannabinoid compounds.

FDA Approval 64

FDA Approval Protein Containment Genetic Disease 64

The Pharma Data

MAY 27, 2022

AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Vaccination 52

Vaccination Vaccine Immune Response Medicine 52

The Pharma Data

JANUARY 11, 2021

Neither of the two vaccines approved in the United States — made by Pfizer-BioNTech and Moderna — contains the live virus. They give the body a blueprint to create a bit of the virus that causes COVID-19, called a spike protein. This protein then appears on the surface of the cell and the immune system responds to it. .

Vaccination 52

Vaccination Vaccine Allergies Protein 52

The Pharma Data

JULY 28, 2021

The results are in line with recent reports in the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Report, the UK system for collecting and monitoring information on safety concerns, which also show low rates of TTS after a second dose. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Vaccination 52

Vaccination Vaccine Protein Medicine 52

pharmaphorum

NOVEMBER 9, 2021

Opdivo is a PD-1 inhibitor that works against the protein, Programmed Death-Ligand 1 (PD-L1), which is found on the surface of many cells throughout the body. Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system. These patients had a median overall survival (OS) of 24.6

FDA Approval 58

FDA Approval Trials Containment Medicine 58

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

SEPTEMBER 28, 2020

NHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it the first and only medicine backed for what is the most common inherited bleeding disorder in the UK. Dr Carolyn Millar.

Drugs 68

Drugs Containment Production Protein 68

The Pharma Data

OCTOBER 20, 2020

Patent and Trademark Office covering the use of Fatty Acid Binding Protein 5 (FABP5) inhibitors for the treatment of psychological disorders such as anxiety and post-traumatic stress disorder (PTSD). Chronic stress and anxiety disorders, including PTSD, represent significant healthcare and economic burdens worldwide.

Protein 52

Protein Development Research Production 52

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98